Products for Research Use Only
RegisterLogin

Riviciclib

CAT: 0804-HY-16559ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16559ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib shows antitumor activity on cisplatin-resistant cells[3].
CAS Number
920113-02-6
Product Name Alternative
P276-00 (free base)
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Riviciclib.html
Solubility
10 mM in DMSO
Smiles
O=C1C=C(C2=C(Cl)C=CC=C2)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13
Molecular Formula
C21H20ClNO5
Molecular Weight
401.84
References & Citations
[1]Roskoski R Jr, Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.|[2]Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6 (3) :918-25.|[3]Joshi KS, et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6 (3) :926-34.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK6; CDK9
Citation 01
Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|Elife. 2020 Dec 7;9:e61405.|Pharmaceuticals (Basel) . 2024 Apr 29;17 (5) :569.

Alternative Products

CatalogName
MBS3606597-01Riviciclib
202118Riviciclib HCl
T6924-01Riviciclib hydrochloride
S8058-01Riviciclib hydrochloride (P276-00)

Popular Products